Samuel Sciamarelli is a director in BRG Corporate Finance’s Healthcare Transaction Advisory practice, based in New York City. He joined BRG from a Big Four accounting firm, where he spent six years leading both buy- and sell-side healthcare and life sciences transactions on behalf of private equity and strategic clients.
He has primarily focused on advising clients through complex financial transactions by leveraging his financial analysis (quality of earnings, quality of revenue, net working capital, indebtedness, and purchase agreement review), data analytics, and technical accounting skills across deals ranging from $30 million up to $10 billion in enterprise value.
Mr. Sciamarelli’s transaction experience includes both public and private transactions between life sciences and healthcare services. In the life sciences sector, his experience includes laboratory and diagnostics, pharmaceutical development and manufacturing, medical device manufacturing and development, durable medical equipment, contract development and manufacturing, and contract research organizations. In healthcare services, his experience includes multisite vision care, women’s care, home health, skilled nursing and assisted living facilities, hospital systems (including not-for-profit), urgent care, imaging, dialysis, and revenue cycle management.
Mr. Sciamarelli previously worked in audit assurance for three years at a separate Big Four firm, focusing on healthcare technology, financial services, and legal industries.
BRG, Director, June 2022 – Current
KPMG, Director, September 2016 – June 2022
Deloitte, Senior Associate, September 2013 – September 2016
Certified Public Accounting (CPA), New York (inactive)
Areas of Expertise
Long Island University – Brooklyn